Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(12):993; doi:10.1093/jnci/91.12.993
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Arnold, K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Arnold, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 12, 993, June 16, 1999
© 1999 Oxford University Press

NEWS

Substantial Differences Exist in How Trials Were Designed

Katherine Arnold

At the American Society of Clinical Oncology meeting, researchers had their first opportunity to analyze and critique the results of the following five high-dose chemotherapy trials for breast cancer:Go



View larger version (120K):
[in this window]
[in a new window]
  		ASCO plenary session on high-dose chemotherapy trials for breast cancer.

 
• Eastern Cooperative Oncology Group Study

ECOG conducted a study on metastatic breast cancer to examine overall survival, . . . [Full Text of this Article]

• French Study

• Cancer and Leukemia Group B Study

• Scandinavian Study

• South African Study


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?